Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Background: Despite significant advances in understanding the molecular pathways of
glioma, translating this knowledge into effective long-term solutions remains a challenge …

The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to
efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor …

Glioblastoma is the most common malignant primary central nervous system tumor and one
of the most debilitating cancers. The prognosis of patients with glioblastoma remains poor …

Glioblastoma is a highly aggressive and invasive tumor that affects the central nervous
system (CNS). With a five-year survival rate of only 6.9% and a median survival time of eight …

Glioblastoma (GB) is one of the most aggressive and difficult-to-treat brain tumors, with a
poor prognosis and limited treatment options. In recent years, sonodynamic therapy (SDT) …

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median
overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy …

Purpose The prognosis of recurrent glioblastoma (rGBM) is poor, and there is currently no
effective treatment strategy. Sonodynamic therapy (SDT) is a new method for cancer …

Despite the emergence of cutting-edge therapeutic strategies and tremendous progress in
research, a complete cure of glioma remains elusive. The heterogenous nature of tumor …

The blood-brain barrier (BBB) presents a formidable challenge in delivering therapeutic
agents to the central nervous system. Ultrasound-mediated BBB disruption has emerged as …